Bone morphogenetic protein signaling in bone homeostasis

Bone

Volumn 80, Issue , 2015, Pages 43-59

  Sánchez Duffhues, Gonzalo ^a   Hiepen, Christian ^b,c   Knaus, Petra ^b,c   ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

BMP; Bone; Osteoblast; Osteoclast; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYCLIN DEPENDENT KINASE 8; CYCLIN DEPENDENT KINASE 9; CYTOKINE; GROWTH FACTOR; LIGAND; MEMBRANE RECEPTOR; SMAD PROTEIN; SOMATOMEDIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

BONE DISEASE; BONE HOMEOSTASIS; BONE REMODELING; BONE TISSUE; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; FRACTURE; GENE EXPRESSION; HETEROTOPIC OSSIFICATION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MECHANICAL STRESS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; BONE; CYTOLOGY; METABOLISM;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; HUMANS; OSTEOBLASTS; OSTEOCLASTS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84943659307     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.05.025     Document Type: Review

References (339)

1. Sims N.A., Martin T.J. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep 2014, 3:481.
2. Parfitt A.M. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002, 30:5-7.
3. Chim S.M., Tickner J., Chow S.T., Kuek V., Guo B., Zhang G., et al. Angiogenic factors in bone local environment. Cytokine Growth Factor Rev 2013, 24:297-310.
4. Jensen P.R., Andersen T.L., Søe K., Hauge E.M., Bollerslev J., Amling M., et al. Premature loss of bone remodeling compartment canopies is associated with deficient bone formation: a study of healthy individuals and patients with Cushing's syndrome. J Bone Miner Res 2012, 27:770-780.
5. Kusumbe A.P., Ramasamy S.K., Adams R.H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 2014, 507:323-328.
6. Ramasamy S.K., Kusumbe A.P., Wang L., Adams R.H. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 2014, 507:376-380.
7. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999, 5:623-628.
8. Ai-Aql Z.S., Alagl A.S., Graves D.T., Gerstenfeld L.C., Einhorn T.A. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 2008, 87:107-118.
9. Pacicca D.M., Patel N., Lee C., Salisbury K., Lehmann W., Carvalho R., et al. Expression of angiogenic factors during distraction osteogenesis. Bone 2003, 33:889-898.
10. Maes C. Role and regulation of vascularization processes in endochondral bones. Calcif Tissue Int 2013, 92:307-323.
11. Saran U., Gemini Piperni S., Chatterjee S. Role of angiogenesis in bone repair. Arch Biochem Biophys 2014, 561:109-117.
12. Weitzmann M.N., Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci 2007, 1116:360-375.
13. Abou-Khalil R., Colnot C. Cellular and molecular bases of skeletal regeneration: what can we learn from genetic mouse models?. Bone 2014, 64:211-221.
14. Danks L., Takayanagi H. Immunology and bone. J Biochem 2013, 154:29-39.
15. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling. J Biol Chem 2010, 285:25103-25108.
16. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
17. Medici D., Shore E.M., Lounev V.Y., Kaplan F.S., Kalluri R., Olsen B.R. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010, 16:1400-1406.
18. Teitelbaum S. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
19. Khan U.A., Hashimi S.M., Bakr M.M., Forwood M.R., Morrison N.A. Foreign body giant cells and osteoclasts are TRAP positive, have podosome-belts and both require OC-STAMP for cell fusion. J Cell Biochem 2013, 114:1772-1778.
20. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Jones S.J., et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988, 122:1373-1382.
21. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
22. Katagiri T., Tsukamoto S. The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway. Biol Chem 2013, 394:703-714.
23. Lissenberg-Thunnissen S.N., de Gorter D.J.J., Sier C.F.M., Schipper I.B. Use and efficacy of bone morphogenetic proteins in fracture healing. Int Orthop 2011, 35:1271-1280.
24. Daluiski A., Engstrand T., Bahamonde M.E., Gamer L.W., Agius E., Stevenson S.L., et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 2001, 27:84-88.
25. Shen B., Bhargav D., Wei A., Williams L.A., Tao H., Ma D.D.F., et al. BMP-13 emerges as a potential inhibitor of bone formation. Int J Biol Sci 2009, 5:192-200.
26. Cheng H., Jiang W., Phillips F.M., Haydon R.C., Peng Y., Zhou L., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg 2003, 85-A:1544-1552.
27. Simic P., Culej J.B., Orlic I., Grgurevic L., Draca N., Spaventi R., et al. Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J Biol Chem 2006, 281:25509-25521.
28. van Baardewijk L.J., van der Ende J., Lissenberg-Thunnissen S., Romijn L.M., Hawinkels L.J.A.C., Sier C.F.M., et al. Circulating bone morphogenetic protein levels and delayed fracture healing. Int Orthop 2013, 37:523-527.
29. Grgurevic L., Macek B., Healy D.R., Brault A.L., Erjavec I., Cipcic A., et al. Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis. J Am Soc Nephrol 2011, 22:681-692.
30. Mueller T.D., Nickel J. Promiscuity and specificity in BMP receptor activation. FEBS Lett 2012, 586:1846-1859.
31. Shi M., Zhu J., Wang R., Chen X., Mi L., Walz T., et al. Latent TGF-β structure and activation. Nature 2011, 474:343-349.
32. Sengle G., Charbonneau N.L., Ono R.N., Sasaki T., Alvarez J., Keene D.R., et al. Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 2008, 283:13888.
33. Bragdon B., Moseychuk O., Saldanha S., King D., Julian J., Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal 2011, 23:609-620.
34. Saremba S., Nickel J., Seher A., Kotzsch A., Sebald W., Mueller T.D. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J 2008, 275:172-183.
35. Garrigue-Antar L., Hartigan N., Kadler K.E. Post-translational modification of bone morphogenetic protein-1 is required for secretion and stability of the protein. J Biol Chem 2002, 277:43327-43334.
36. Hashimoto O., Moore R.K., Shimasaki S. Posttranslational processing of mouse and human BMP-15: potential implication in the determination of ovulation quota. Proc Natl Acad Sci U S A 2005, 102:5426-5431.
37. Carreira A.C., Lojudice F.H., Halcsik E., Navarro R.D., Sogayar M.C., Granjeiro J.M. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res 2014, 93:335-345.
38. Little S.C., Mullins M.C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 2009, 11:637-643.
39. Sieber C., Kopf J., Hiepen C., Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 2009, 20:343-355.
40. Avsian-Kretchmer O., Hsueh A.J.W. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol 2004, 18:1-12.
41. Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 2006, 1068:19-25.
42. Dimitriou R., Tsiridis E., Carr I., Simpson H., Giannoudis P.V. The role of inhibitory molecules in fracture healing. Injury 2006, 37(Suppl. 1):S20-S29.
43. Bell E., Muñoz-Sanjuán I., Altmann C.R., Vonica A., Brivanlou A.H. Cell fate specification and competence by Coco, a maternal BMP, TGF-β and Wnt inhibitor. Development 2003, 130:1381-1389.
44. Yanagita M., Oka M., Watabe T., Iguchi H., Niida A., Takahashi S., et al. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem Biophys Res Commun 2004, 316:490-500.
45. Geng Y., Dong Y., Yu M., Zhang L., Yan X., Sun J., et al. Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proc Natl Acad Sci U S A 2011, 108:7058-7063.
46. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003, 278:24113-24117.
47. Zebboudj A.F., Imura M., Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002, 277:4388-4394.
48. Lin J., Patel S.R., Cheng X., Cho E.A., Levitan I., Ullenbruch M., et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 2005, 11:387-393.
49. Yao Y., Jumabay M., Ly A., Radparvar M., Wang A.H., Abdmaulen R., et al. Crossveinless 2 regulates bone morphogenetic protein 9 in human and mouse vascular endothelium. Blood 2012, 119:5037-5047.
50. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., Riddle D.L., et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 1994, 269:16985-16988.
51. Wrana J.L., Tran H., Attisano L., Arora K., Childs S.R., Massagué J., et al. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an Activin receptor complex. Mol Cell Biol 1994, 14:944-950.
52. Massagué J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000, 1:169-178.
53. Sebald W., Nickel J., Zhang J.-L., Mueller T.D. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 2004, 385:697-710.
54. Upton P.D., Morrell N.W. TGF-β and BMPR-II pharmacology-implications for pulmonary vascular diseases. Curr Opin Pharmacol 2009, 9:274-280.
55. Guzman A., Zelman-Femiak M., Boergermann J.H., Paschkowsky S., Kreuzaler P.A., Fratzl P., et al. SMAD versus non-SMAD signaling is determined by lateral mobility of bone morphogenetic protein (BMP) receptors. J Biol Chem 2012, 287:39492-39504.
56. Hassel S., Schmitt S., Hartung A., Roth M., Nohe A., Petersen N., et al. Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg 2003, 85-A(Suppl. 3):44-51.
57. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I., et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002, 277:5330-5338.
58. Nishinakamura R., Matsumoto Y., Uochi T.A., Asashima M., Yokota T. Xenopus FK506-binding protein homolog induces a secondary axis in frog embryos, which is inhibited by coexisting BMP-4 signaling. Biochem Biophys Res Commun 1997, 239:585-591.
59. Huse M., Chen Y.G., Massagué J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF-β receptor in complex with FKBP12. Cell 1999, 96:425-436.
60. Akiyama S., Katagiri T., Namiki M., Yamaji N., Yamamoto N., Miyama K., et al. Constitutively active BMP type I receptors transduce BMP-2 signals without the ligand in C2C12 myoblasts. Exp Cell Res 1997, 235:362-369.
61. Wieser R., Wrana J.L., Massagué J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J 1995, 14:2199-2208.
62. Miyazono K., Maeda S., Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005, 16:251-263.
63. Sánchez-Duffhues G., García de Vinuesa A., ten Dijke P. Bone morphogenetic proteins signal transduction in vascular diseases 2012, Nova Science Publishers.
64. Scharpfenecker M., van Dinther M., Liu Z., van Bezooijen R.L., Zhao Q., Pukac L., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007, 120:964-972.
65. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 2005, 280:25111-25118.
66. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A 1995, 92:7632-7636.
67. Bilandzic M., Stenvers K.L. Betaglycan: a multifunctional accessory. Mol Cell Endocrinol 2011, 339:180-189.
68. ten Dijke P., Goumans M.-J., Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008, 11:79-89.
69. Kirkbride K.C., Townsend T.A., Bruinsma M.W., Barnett J.V., Blobe G.C. Bone morphogenetic proteins signal through the transforming growth factor-β type III receptor. J Biol Chem 2008, 283:7628.
70. Castonguay R., Werner E.D., Matthews R.G., Presman E., Mulivor A.W., Solban N., et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011, 286:30034-30046.
71. Blanco F.J., Santibanez J.F., Guerrero-Esteo M., Langa C., Vary C.P.H., Bernabéu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-β receptor complex. J Cell Physiol 2005, 204:574-584.
72. Yeo C., Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell 2001, 7:949-957.
73. Babitt J.L., Zhang Y., Samad T.A., Xia Y., Tang J., Campagna J.A., et al. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem 2005, 280:29820-29827.
74. Samad T.A., Rebbapragada A., Bell E., Zhang Y., Sidis Y., Jeong S.-J., et al. DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem 2005, 280:14122-14129.
75. Corradini E., Babitt J.L., Lin H.Y. The RGM/DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev 2009, 20:398.
76. Biver E., Thouverey C., Magne D., Caverzasio J. Crosstalk between tyrosine kinase receptors, GSK3 and BMP2 signaling during osteoblastic differentiation of human mesenchymal stem cells. Mol Cell Endocrinol 2014, 382:120-130.
77. Zhou J., Lee P.L., Lee C.I., Wei S.Y., Lim S.H., Lin T.E., et al. BMP receptor-integrin interaction mediates responses of vascular endothelial Smad1/5 and proliferation to disturbed flow. J Thromb Haemost 2013, 11:741-755.
78. Hassel S., Yakymovych M., Hellman U., Rönnstrand L., Knaus P., Souchelnytskyi S. Interaction and functional cooperation between the serine/threonine kinase bone morphogenetic protein type II receptor with the tyrosine kinase stem cell factor receptor. J Cell Physiol 2006, 206:457-467.
79. Sammar M., Stricker S., Schwabe G.C., Sieber C., Hartung A., Hanke M., et al. Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 2004, 9:1227-1238.
80. Jin G., Westphalen C.B., Hayakawa Y., Worthley D.L., Asfaha S., Yang X., et al. Progastrin stimulates colonic cell proliferation via CCK2R- and β-arrestin-dependent suppression of BMP2. Gastroenterology 2013, 145(820-830):e10.
81. Liu C., Goswami M., Talley J., Chesser-Martinez P.L., Lou C.H., Sater A.K. TAK1 promotes BMP4/Smad1 signaling via inhibition of ERK MAPK: a new link in the FGF/BMP regulatory network. Differentiation 2012, 83:210-219.
82. Wang Z., Hutton W.C., Yoon S.T. Bone morphogenetic protein-7 antagonizes tumor necrosis factor-α-induced activation of NF-κB and up-regulation of the ADAMTS, leading to decreased degradation of disc matrix macromolecules aggrecan and collagen II. Spine J 2014, 14:505-512.
83. Oshimori N., Fuchs E. Paracrine TGF-β; signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Stem Cells 2012, 10:63-75.
84. Schwappacher R., Weiske J., Heining E., Ezerski V., Marom B., Henis Y.I., et al. Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. EMBO J 2009, 28:1537-1550.
85. Nakashima K., Yanagisawa M., Arakawa H., Kimura N., Hisatsune T., Kawabata M., et al. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999, 284:479-482.
86. Ulloa L., Doody J., Massagué J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999, 397:710-713.
87. Liu Y., Ren W., Warburton R., Toksoz D., Fanburg B.L. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J 2009, 23:2299-2306.
88. Moreno-Miralles I., Schisler J.C., Patterson C. New insights into bone morphogenetic protein signaling: focus on angiogenesis. Curr Opin Hematol 2009, 16:195-201.
89. Shin M., Nagai H., Sheng G. Notch mediates Wnt and BMP signals in the early separation of smooth muscle progenitors and blood/endothelial common progenitors. Development 2009, 136:595-603.
90. Yeh L.C., Lee J.C. Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells. Mol Cell Endocrinol 1999, 153:113-124.
91. Ruschke K., Hiepen C., Becker J., Knaus P. BMPs are mediators in tissue crosstalk of the regenerating musculoskeletal system. Cell Tissue Res 2012, 347:521-544.
92. Yeh L.C., Adamo M.L., Duan C., Lee J.C. Osteogenic protein-1 regulates insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-5 (IGFBP-5) gene expression in fetal rat calvaria cells by different mechanisms. J Cell Physiol 1998, 175:78-88.
93. Zhang R., Oyajobi B.O., Harris S.E., Chen D., Tsao C., Deng H.-W., et al. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013, 52:145-156.
94. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008, 105:20764-20769.
95. Fujita K.-I., Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007, 6:71.
96. Rawadi G., Vayssière B., Dunn F., Baron R., Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003, 18:1842-1853.
97. Baker J.C., Beddington R.S., Harland R.M. Wnt signaling in Xenopus embryos inhibits BMP4 expression and activates neural development. Genes Dev 1999, 13:3149-3159.
98. Kuroda K., Kuang S., Taketo M.M., Rudnicki M.A. Canonical Wnt signaling induces BMP-4 to specify slow myofibrogenesis of fetal myoblasts. Skelet Muscle 2013, 3:5.
99. Lee G.T., Kang D.I., Ha Y.-S., Jung Y.S., Chung J., Min K., et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer 2014, 110:1634-1644.
100. Haegele L., Ingold B., Naumann H., Tabatabai G., Ledermann B., Brandner S. Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression. Mol Cell Neurosci 2003, 24:696-708.
101. Stewart S., Gomez A.W., Armstrong B.E., Henner A., Stankunas K. Sequential and opposing activities of Wnt and BMP coordinate zebrafish bone regeneration. Cell Rep 2014, 6:482-498.
102. Zhou S., Eid K., Glowacki J. Cooperation between TGF-β and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res 2004, 19:463-470.
103. Dong Y., Drissi H., Chen M., Chen D., Zuscik M.J., Schwarz E.M., et al. Wnt-mediated regulation of chondrocyte maturation: modulation by TGF-β. J Cell Biochem 2005, 95:1057-1068.
104. Fuentealba L.C., Eivers E., Ikeda A., Hurtado C., Kuroda H., Pera E.M., et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 2007, 131:980-993.
105. Perez V.A., Ali Z., Alastalo T.-P., Ikeno F., Sawada H., Lai Y.-J., et al. BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. J Cell Biol 2011, 192:171-188.
106. Song J., McColl J., Camp E., Kennerley N., Mok G.F., McCormick D., et al. Smad1 transcription factor integrates BMP2 and Wnt3a signals in migrating cardiac progenitor cells. Proc Natl Acad Sci U S A 2014, 111:7337-7342.
107. Fischer L., Boland G., Tuan R.S. Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. J Cell Biochem 2002, 84:816-831.
108. Itasaki N., Hoppler S. Crosstalk between Wnt and bone morphogenic protein signaling: a turbulent relationship. Dev Dyn 2010, 239:16-33.
109. Bain G., Müller T., Wang X., Papkoff J. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 2003, 301:84-91.
110. Tian Q., He X.C., Hood L., Li L. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3ζ. Cell Cycle 2005, 4:215-216.
111. Onichtchouk D., Chen Y.G., Dosch R., Gawantka V., Delius H., Massagué J., et al. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature 1999, 401:480-485.
112. Wilkinson L., Kolle G., Wen D., Piper M., Scott J., Little M. CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 2003, 278:34181-34188.
113. Hagihara M., Endo M., Hata K., Higuchi C., Takaoka K., Yoshikawa H., et al. Neogenin, a receptor for bone morphogenetic proteins. J Biol Chem 2011, 286:5157-5165.
114. Paralkar V.M., Weeks B.S., Yu Y.M., Kleinman H.K., Reddi A.H. Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: potentiation and binding to type IV collagen. J Cell Biol 1992, 119:1721-1728.
115. Wang X., Harris R.E., Bayston L.J., Ashe H.L. Type IV collagens regulate BMP signalling in Drosophila. Nature 2008, 455:72-77.
116. Gregory K.E., Ono R.N., Charbonneau N.L., Kuo C.L., Keene D.R., Bächinger H.P., et al. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 2005, 280:27970-27980.
117. Nistala H., Lee-Arteaga S., Smaldone S., Siciliano G., Carta L., Ono R.N., et al. Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation. J Cell Biol 2010, 190:1107-1121.
118. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 2011, 3:100ra89-9.
119. Peluso C.E., Umulis D., Kim Y.-J., O'Connor M.B., Serpe M. Shaping BMP morphogen gradients through enzyme-substrate interactions. Dev Cell 2011, 21:375-383.
120. d'Amaro R., Scheidegger R., Blumer S., Pazera P., Katsaros C., Graf D., et al. Putative functions of extracellular matrix glycoproteins in secondary palate morphogenesis. Front Phys 2012, 3:377.
121. Seib F.P., Lanfer B., Bornhäuser M., Werner C. Biological activity of extracellular matrix-associated BMP-2. J Tissue Eng Regen Med 2010, 4:324-327.
122. Kisiel M., Klar A.S., Ventura M., Buijs J., Mafina M.-K., Cool S.M., et al. Complexation and sequestration of BMP-2 from an ECM mimetic hyaluronan gel for improved bone formation. PLoS One 2013, 8:e78551.
123. Rodenberg E., Azhdarinia A., Lazard Z.W., Hall M., Kwon S.K., Wilganowski N., et al. Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model. Tissue Eng Part A 2011, 17:2487-2496.
124. Mao L., Yano M., Kawao N., Tamura Y., Okada K., Kaji H. Role of matrix metalloproteinase-10 in the BMP-2 inducing osteoblastic differentiation. Endocr J 2013, 60:1309-1319.
125. Sun L., Rajamannan N.M., Sucosky P. Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease. PLoS One 2013, 8:e84433.
126. Schmierer B., Hill C.S. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007, 8:970-982.
127. Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. Nat Struct Biol 2001, 8:248-253.
128. Korchynskyi O., ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 2002, 277:4883-4891.
129. Shin M., Ohte S., Fukuda T., Sasanuma H., Yoneyama K., Kokabu S., et al. Identification of a novel bone morphogenetic protein (BMP)-inducible transcript, BMP-inducible transcript-1, by utilizing the conserved BMP-responsive elements in the Id genes. J Bone Miner Metab 2013, 31:34-43.
130. López-Rovira T., Chalaux E., Massagué J., Rosa J.L., Ventura F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J Biol Chem 2002, 277:3176-3185.
131. Duan X., Liang Y.Y., Feng X.H., Lin X. Protein serine/threonine phosphatase PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signaling pathway. J Biol Chem 2006, 281:36526-36532.
132. Kokabu S., Nojima J., Kanomata K., Ohte S., Yoda T., Fukuda T., et al. Protein phosphatase magnesium-dependent 1A-mediated inhibition of BMP signaling is independent of Smad dephosphorylation. J Bone Miner Res 2010, 25:653-660.
133. Sapkota G., Knockaert M., Alarcon C., Montalvo E., Brivanlou A.H., Massagué J. Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-β pathways. J Biol Chem 2006, 281:40412-40419.
134. Sapkota G., Alarcón C., Spagnoli F.M., Brivanlou A.H., Massagué J. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell 2007, 25:441-454.
135. Alarcón C., Zaromytidou A.-I., Xi Q., Gao S., Yu J., Fujisawa S., et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell 2009, 139:757-769.
136. Xu P., Liu J., Derynck R. Post-translational regulation of TGF-β receptor and Smad signaling. FEBS Lett 2012, 586:1871-1884.
137. Dupont S., Inui M., Newfeld S.J. Regulation of TGF-β signal transduction by mono- and deubiquitylation of Smads. FEBS Lett 2012, 586:1913-1920.
138. De Boeck M., ten Dijke P. Key role for ubiquitin protein modification in TGF-β signal transduction. Ups J Med Sci 2012, 117:153-165.
139. Zhu H., Kavsak P., Abdollah S., Wrana J.L., Thomsen G.H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999, 400:687-693.
140. Sangadala S., Boden S.D., Viggeswarapu M., Liu Y., Titus L. LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurf1 resulting in decreased ubiquitination of Smads. J Biol Chem 2006, 281:17212-17219.
141. Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 2001, 98:974-979.
142. Li L., Xin H., Xu X., Huang M., Zhang X., Chen Y., et al. CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. Mol Cell Biol 2004, 24:856-864.
143. Schwartz A.L., Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009, 49:73-96.
144. Inui M., Manfrin A., Mamidi A., Martello G., Morsut L., Soligo S., et al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol 2011, 13:1368-1375.
145. Tang L.-Y., Yamashita M., Coussens N.P., Tang Y., Wang X., Li C., et al. Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3. EMBO J 2011, 30:4777-4789.
146. Zhang J., Zhang X., Xie F., Zhang Z., van Dam H., Zhang L., et al. The regulation of TGF-β/SMAD signaling by protein deubiquitination. Protein Cell 2014, 5:503-517.
147. Hata A., Lagna G., Massagué J., Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998, 12:186-197.
148. Xu J., Wang A.H., Oses-Prieto J., Makhijani K., Katsuno Y., Pei M., et al. Arginine methylation initiates BMP-induced Smad signaling. Mol Cell 2013, 51:5-19.
149. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol Cell 2000, 6:1365-1375.
150. Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T., et al. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001, 276:12477-12480.
151. Bengtsson L., Schwappacher R., Roth M., Boergermann J.H., Hassel S., Knaus P. PP2A regulates BMP signalling by interacting with BMP receptor complexes and by dephosphorylating both the C-terminus and the linker region of Smad1. J Cell Sci 2009, 122:1248-1257.
152. Ortuño M.J., Ruiz-Gaspà S., Rodríguez-Carballo E., Susperregui A.R.G., Bartrons R., Rosa J.L., et al. p38 regulates expression of osteoblast-specific genes by phosphorylation of osterix. J Biol Chem 2010, 285:31985-31994.
153. Lee-Hoeflich S.T., Causing C.G., Podkowa M., Zhao X., Wrana J.L., Attisano L. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J 2004, 23:4792-4801.
154. Gamell C., et al. BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity. J Cell Sci 2008, 121(Pt 23):3960-3970.
155. Wang Y.-K., Yu X., Cohen D.M., Wozniak M.A., Yang M.T., Gao L., et al. Bone morphogenetic protein-2-induced signaling and osteogenesis is regulated by cell shape, RhoA/ROCK, and cytoskeletal tension. Stem Cells Dev 2012, 21:1176-1186.
156. Guo X., Wang X.-F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res 2009, 19:71-88.
157. Tang Y., Xie H., Chen J., Geng L., Chen H., Li X., et al. Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling 2013, 22:668-678.
158. Li Y., Li A., Strait K., Zhang H., Nanes M.S., Weitzmann M.N. Endogenous TNF-α lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-κB. J Bone Miner Res 2007, 22:646-655.
159. Kopf J., Paarmann P., Hiepen C., Horbelt D., Knaus P. BMP growth factor signaling in a biomechanical context. Biofactors 2014, 40:171-187.
160. Dodge T., Wanis M., Ayoub R., Zhao L., Watts N.B., Bhattacharya A., et al. Mechanical loading, damping, and load-driven bone formation in mouse tibiae. Bone 2012, 51:810-818.
161. Warden S.J., Mantila Roosa S.M., Kersh M.E., Hurd A.L., Fleisig G.S., Pandy M.G., et al. Physical activity when young provides lifelong benefits to cortical bone size and strength in men. Proc Natl Acad Sci U S A 2014, 111:5337-5342.
162. Padilla F., Puts R., Vico L., Raum K. Stimulation of bone repair with ultrasound: a review of the possible mechanic effects. Ultrasonics 2014, 54:1125-1145.
163. Schwarz C., Wulsten D., Ellinghaus A., Lienau J., Willie B.M., Duda G.N. Mechanical load modulates the stimulatory effect of BMP2 in a rat nonunion model. Tissue Eng Part A 2013, 19:247-254.
164. Kamioka H., Kameo Y., Imai Y., Bakker A.D., Bacabac R.G., Yamada N., et al. Microscale fluid flow analysis in a human osteocyte canaliculus using a realistic high-resolution image-based three-dimensional model. Integr Biol 2012, 4:1198-1206.
165. Hum J.M., Day R.N., Bidwell J.P., Wang Y., Pavalko F.M. Mechanical loading in osteocytes induces formation of a Src/Pyk2/MBD2 complex that suppresses anabolic gene expression. PLoS One 2014, 9:e97942.
166. Lau K.-H.W., Kapur S., Kesavan C., Baylink D.J. Up-regulation of the Wnt, estrogen receptor, insulin-like growth factor-I, and bone morphogenetic protein pathways in C57BL/6J osteoblasts as opposed to C3H/HeJ osteoblasts in part contributes to the differential anabolic response to fluid shear. J Biol Chem 2006, 281:9576-9588.
167. Kopf J., Petersen A., Duda G.N., Knaus P. BMP2 and mechanical loading cooperatively regulate immediate early signalling events in the BMP pathway. BMC Biol 2012, 10:37.
168. Papanicolaou S.E., Phipps R.J., Fyhrie D.P., Genetos D.C. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 2009, 46:389-399.
169. Nomura S., Takano-Yamamoto T. Molecular events caused by mechanical stress in bone. Matrix Biol 2000, 19:91-96.
170. Santos A., Bakker A.D., Willems H.M.E., Bravenboer N., Bronckers A.L.J.J., Klein-Nulend J. Mechanical loading stimulates BMP7, but not BMP2, production by osteocytes. Calcif Tissue Int 2011, 89:318-326.
171. Lu H.-F., Mai Z.-H., Xu Y., Wang W., Ai H. Mechanical loading induced expression of bone morphogenetic protein-2, alkaline phosphatase activity, and collagen synthesis in osteoblastic MC3T3-E1 cells. Chin Med J 2012, 125:4093-4097.
172. Zhou J., Lee P.L., Tsai C., Lee C.I., Yang T.L., Chuang H.S., et al. Force-specific activation of Smad1/5 regulates vascular endothelial cell cycle progression in response to disturbed flow. Proc Natl Acad Sci U S A 2012, 109:7770-7775.
173. Maeda S., Hayashi M., Komiya S., Imamura T., Miyazono K. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004, 23:552-563.
174. Centrella M., Casinghino S., Kim J., Pham T., Rosen V., Wozney J., et al. Independent changes in type I and type II receptors for transforming growth factor-β induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype. Mol Cell Biol 1995, 15:3273-3281.
175. Zhang H., Bradley A. Mice deficient for BMP2 are non-viable and have defects in amnion/chorion and cardiac development. Development 1996, 122:2977-2986.
176. Mishina Y., Suzuki A., Ueno N., Behringer R.R. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 1995, 9:3027-3037.
177. Tsuji K., Bandyopadhyay A., Harfe B.D., Cox K., Kakar S., Gerstenfeld L., et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006, 38:1424-1429.
178. Bandyopadhyay A., Tsuji K., Cox K., Harfe B.D., Rosen V., Tabin C.J. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet 2006, 2:e216.
179. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfα1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
180. Choi J.Y., Pratap J., Javed A., Zaidi S.K., Xing L., Balint E., et al. Subnuclear targeting of Runx/Cbfα/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci U S A 2001, 98:8650-8655.
181. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
182. Zhou X., Zhang Z., Feng J.Q., Dusevich V.M., Sinha K., Zhang H., et al. Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci U S A 2010, 107:12919-12924.
183. Cheng S.-L., Shao J.-S., Charlton-Kachigian N., Loewy A.P., Towler D.A. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 2003, 278:45969-45977.
184. Satokata I., Ma L., Ohshima H., Bei M., Woo I., Nishizawa K., et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 2000, 24:391-395.
185. Wilkie A.O., Tang Z., Elanko N., Walsh S., Twigg S.R., Hurst J.A., et al. Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. Nat Genet 2000, 24:387-390.
186. Franceschi R.T., Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003, 88:446-454.
187. Bi W., Deng J.M., Zhang Z., Behringer R.R., de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet 1999, 22:85-89.
188. Akiyama H., Kim J.-E., Nakashima K., Balmes G., Iwai N., Deng J.M., et al. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. Proc Natl Acad Sci U S A 2005, 102:14665-14670.
189. Jeon M.J., Kim J.A., Kwon S.H., Kim S.W., Park K.S., Park S.-W., et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003, 278:23270-23277.
190. Shockley K.R., Lazarenko O.P., Czernik P.J., Rosen C.J., Churchill G.A., Lecka-Czernik B. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232-246.
191. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 2004, 117:387-398.
192. Glass D.A., Karsenty G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol 2006, 73:43-84.
193. Lee K.S., Kim H.J., Li Q.L., Chi X.Z., Ueta C., Komori T., et al. Runx2 is a common target of transforming growth factor-β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000, 20:8783-8792.
194. Nishimura R., Hata K., Harris S.E., Ikeda F., Yoneda T. Core-binding factor α 1 (Cbfα1) induces osteoblastic differentiation of C2C12 cells without interactions with Smad1 and Smad5. Bone 2002, 31:303-312.
195. Zhang Y.W., Yasui N., Ito K., Huang G., Fujii M., Hanai J., et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A 2000, 97:10549-10554.
196. Matsubara T., Kida K., Yamaguchi A., Hata K., Ichida F., Meguro H., et al. BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem 2008, 283:29119-29125.
197. Kang J.S., Alliston T., Delston R., Derynck R. Repression of Runx2 function by TGF-β through recruitment of class II histone deacetylases by Smad3. EMBO J 2005, 24:2543-2555.
198. Spinella-Jaegle S., Roman-Roman S., Faucheu C., Dunn F.W., Kawai S., Gallea S., et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-β1 on osteoblast differentiation. Bone 2001, 29:323-330.
199. Murakami G., Watabe T., Takaoka K., Miyazono K., Imamura T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 2003, 14:2809-2817.
200. Horiki M., Imamura T., Okamoto M., Hayashi M., Murai J., Myoui A., et al. Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia. J Cell Biol 2004, 165:433-445.
201. Shen R., Chen M., Wang Y.-J., Kaneki H., Xing L., O'Keefe R.J., et al. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem 2006, 281:3569-3576.
202. Takase M., Imamura T., Sampath T.K., Takeda K., Ichijo H., Miyazono K., et al. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun 1998, 244:26-29.
203. Takase M., et al. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun 1998, 244(1):26-29.
204. Shirakawa K., Maeda S., Gotoh T., Hayashi M., Shinomiya K., Ehata S., et al. CCAAT/enhancer-binding protein homologous protein (CHOP) regulates osteoblast differentiation. Mol Cell Biol 2006, 26:6105-6116.
205. Li N., Lee W.Y.-W., Lin S.-E., Ni M., Zhang T., Huang X.-R., et al. Partial loss of Smad7 function impairs bone remodeling, osteogenesis and enhances osteoclastogenesis in mice. Bone 2014, 67C:46-55.
206. Wang J.H., Liu Y.Z., Yin L.J., Chen L., Huang J., Liu Y., et al. BMP9 and COX-2 form an important regulatory loop in BMP9-induced osteogenic differentiation of mesenchymal stem cells. Bone 2013, 57:311-321.
207. Lai C.-F., Cheng S.-L. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-β in normal human osteoblastic cells. J Biol Chem 2002, 277:15514-15522.
208. Pertovaara L., et al. Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol 1989, 9(3):1255-1262.
209. Mishina Y., Starbuck M.W., Gentile M.A., Fukuda T., Kasparcova V., Seedor J.G., et al. Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J Biol Chem 2004, 279:27560-27566.
210. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 2003, 88:873-884.
211. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
212. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
213. Wang Z.Q., Ovitt C., Grigoriadis A.E., Möhle-Steinlein U., Rüther U., Wagner E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992, 360:741-745.
214. mi/mi) mice. Mol Cell 2001, 8:749-758.
215. 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005, 208:88-105.
216. Tondravi M.M., McKercher S.R., Anderson K., Erdmann J.M., Quiroz M., Maki R., et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997, 386:81-84.
217. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
218. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997, 11:3482-3496.
219. Iotsova V., Caamaño J., Loy J., Yang Y., Lewin A., Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997, 3:1285-1289.
220. Maeda K., Kobayashi Y., Udagawa N., Uehara S., Ishihara A., Mizoguchi T., et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012, 18:405-412.
221. Albers J., Keller J., Baranowsky A., Beil F.T., Catala-Lehnen P., Schulze J., et al. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol 2013, 200:537-549.
222. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013, 19:179-192.
223. Vaidya R., Weir R., Sethi A., Meisterling S., Hakeos W., Wybo C.D. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence. J Bone Joint Surg Br 2007, 89:342-345.
224. Pradhan B.B., Bae H.W., Dawson E.G., Patel V.V., Delamarter R.B. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine 2006, 31:E277-E284.
225. Seeherman H.J., Li X.J., Bouxsein M.L., Wozney J.M. rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 2010, 92:411-426.
226. Laursen M., Høy K., Hansen E.S., Gelineck J., Christensen F.B., Bünger C.E. Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results. Eur Spine J 1999, 8:485-490.
227. Abe E., Yamamoto M., Taguchi Y., Lecka-Czernik B., O'Brien C.A., Economides A.N., et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 2000, 15:663-673.
228. Itoh K., Udagawa N., Katagiri T., Iemura S., Ueno N., Yasuda H., et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of NF-κB ligand. Endocrinology 2001, 142:3656-3662.
229. Otsuka E., Notoya M., Hagiwara H. Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif Tissue Int 2003, 73:72-77.
230. Paul S., Lee J.C., Yeh L.-C.C. A comparative study on BMP-induced osteoclastogenesis and osteoblastogenesis in primary cultures of adult rat bone marrow cells. Growth Factors 2009, 27:121-131.
231. Okamoto M., Murai J., Yoshikawa H., Tsumaki N. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 2006, 21:1022-1033.
232. Yano M., Kawao N., Okumoto K., Tamura Y., Okada K., Kaji H. Fibrodysplasia ossificans progressiva-related activated Activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues. J Biol Chem 2014, 289:16966-16977.
233. Pham L., Beyer K., Jensen E.D., Rodriguez J.S., Davydova J., Yamamoto M., et al. Bone morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the BMP antagonist, twisted gastrulation. J Cell Biochem 2011, 112:793-803.
234. Kaneko H., Arakawa T., Mano H., Kaneda T., Ogasawara A., Nakagawa M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000, 27:479-486.
235. Zheng Y., Wang L., Zhang X., Zhang X., Gu Z., Wu G. BMP2/7 heterodimer can modulate all cellular events of the in vitro RANKL-mediated osteoclastogenesis, respectively, in different dose patterns. Tissue Eng Part A 2012, 18:621.
236. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994, 843:1-129.
237. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:342.
238. Harada S.-I., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
239. Garrett I.R. Anabolic agents and the bone morphogenetic protein pathway. Curr Top Dev Biol 2007, 78:127-171.
240. Yu B., Zhao X., Yang C., Crane J., Xian L., Lu W., et al. Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling. J Bone Miner Res 2012, 27:2001-2014.
241. Takase H., Yano S., Yamaguchi T., Kanazawa I., Hayashi K., Yamamoto M., et al. Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and Rho kinase inhibition in osteoblastic MC3T3-E1 cells. Horm Metab Res 2009, 41:861-865.
242. Enhanced bone morphogenetic protein-2-induced ectopic and orthotopic bone formation by intermittent parathyroid hormone (1-34) administration 2010, 16:3769-3777.
243. Morgan E.F., Mason Z.D., Bishop G., Davis A.D., Wigner N.A., Gerstenfeld L.C., et al. Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone 2008, 43:1031-1038.
244. Tsiridis E., Morgan E.F., Bancroft J.M., Song M., Kain M., Gerstenfeld L., et al. Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 2007, 25:1193-1203.
245. Nakao Y., Koike T., Ohta Y., Manaka T., Imai Y., Takaoka K. Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3',5-'cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells. Bone 2009, 44:872-877.
246. Kabasawa Y., Asahina I., Gunji A., Omura K. Administration of parathyroid hormone, prostaglandin E2, or 1-α,25-dihydroxyvitamin D3 restores the bone inductive activity of rhBMP-2 in aged rats. DNA Cell Biol 2003, 22:541-546.
247. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
248. Bellido T. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 2006, 6:358-359.
249. Wu X.-B., Li Y., Schneider A., Yu W., Rajendren G., Iqbal J., et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 2003, 112:924-934.
250. Anastasilakis A.D., Polyzos S.A., Avramidis A., Toulis K.A., Papatheodorou A., Terpos E. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol 2010, 72:752-757.
251. Athanasiadis G., Malouf J., Hernandez-Sosa N., Martin-Fernandez L., Catalan M., Casademont J., et al. Linkage and association analyses using families identified a locus affecting an osteoporosis-related trait. Bone 2014, 60:98-103.
252. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
253. Bandyopadhyay A., Yadav P.S., Prashar P. BMP signaling in development and diseases: a pharmacological perspective. Biochem Pharmacol 2013, 85:857-864.
254. Bragdon B., D'Angelo A., Gurski L., Bonor J., Schultz K.L., Beamer W.G., et al. Altered plasma membrane dynamics of bone morphogenetic protein receptor type Ia in a low bone mass mouse model. Bone 2012, 50:189-199.
255. Benisch P., Schilling T., Klein-Hitpass L., Frey S.P., Seefried L., Raaijmakers N., et al. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One 2012, 7:e45142.
256. Lin G.-T., Tseng H.-F., Chang C.-K., Chuang L.-Y., Liu C.-S., Yang C.-H., et al. SNP combinations in chromosome-wide genes are associated with bone mineral density in Taiwanese women. Chin J Physiol 2008, 51:32-41.
257. Medici M., van Meurs J.B., Rivadeneira F., Zhao H., Arp P.P., Hofman A., et al. BMP-2 gene polymorphisms and osteoporosis: the Rotterdam Study. J Bone Miner Res 2006, 21:845-854.
258. Moffett S.P., Dillon K.A., Yerges L.M., Goodrich L.J., Nestlerode C., Bunker C.H., et al. Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes. Bone 2009, 44:999-1002.
259. Mendoza N., Quereda F., Presa J., Salamanca A., Sánchez-Borrego R., Vázquez F., et al. Estrogen-related genes and postmenopausal osteoporosis risk. Climacteric 2012, 15:587-593.
260. Prall W.C., Haasters F., Heggebö J., Polzer H., Schwarz C., Gassner C., et al. Mesenchymal stem cells from osteoporotic patients feature impaired signal transduction but sustained osteoinduction in response to BMP-2 stimulation. Biochem Biophys Res Commun 2013, 440:617-622.
261. Li C., Yang X., He Y., Ye G., Li X., Zhang X., et al. Bone morphogenetic protein-9 induces osteogenic differentiation of rat dental follicle stem cells in P38 and ERK1/2 MAPK dependent manner. Int J Med Sci 2012, 9:862-871.
262. Osyczka A.M., Leboy P.S. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology 2005, 146:3428-3437.
263. Gallea S., Lallemand F., Atfi A., Rawadi G., Ramez V., Spinella-Jaegle S., et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001, 28:491-498.
264. Haasters F., Docheva D., Gassner C., Popov C., Böcker W., Mutschler W., et al. Mesenchymal stem cells from osteoporotic patients reveal reduced migration and invasion upon stimulation with BMP-2 or BMP-7. Biochem Biophys Res Commun 2014, 452:118-123.
265. Urist M.R., Hudak R.T., Huo Y.K., Rasmussen J.K. Osteoporosis: a bone morphogenetic protein auto-immune disorder. Prog Clin Biol Res 1985, 187:77-96.
266. Kanatani M., Sugimoto T., Kaji H., Kobayashi T., Nishiyama K., Fukase M., et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995, 10:1681-1690.
267. Jensen E.D., Gopalakrishnan R., Westendorf J.J. Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J Biol Chem 2009, 284:2225-2234.
268. Granholm S., Henning P., Lindholm C., Lerner U.H. Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. Bone 2013, 52:83-92.
269. Okamoto M., Murai J., Imai Y., Ikegami D., Kamiya N., Kato S., et al. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 2011, 26:2511-2522.
270. Sotillo Rodriguez J.E., Mansky K.C., Jensen E.D., Carlson A.E., Schwarz T., Pham L., et al. Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling. J Bone Miner Res 2009, 24:1917-1926.
271. Broege A., Pham L., Jensen E.D., Emery A., Huang T.-H., Stemig M., et al. Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis. J Biol Chem 2013, 288:37230-37240.
272. Fong D., Bisson M., Laberge G., McManus S., Grenier G., Faucheux N., et al. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro. Cell Signal 2013, 25:717-728.
273. Maurer T., Zimmermann G., Maurer S., Stegmaier S., Wagner C., Hänsch G.M. Inhibition of osteoclast generation: a novel function of the bone morphogenetic protein 7/osteogenic protein 1. Mediators Inflamm 2012, 2012:1-9.
274. Miyazaki T., Tokimura F., Tanaka S. A review of denosumab for the treatment of osteoporosis. Patient Prefer Adher 2014, 8:463-471.
275. Spector J.A., Luchs J.S., Mehrara B.J., Greenwald J.A., Smith L.P., Longaker M.T. Expression of bone morphogenetic proteins during membranous bone healing. Plast Reconstr Surg 2001, 107:124-134.
276. Shefelbine S.J., Augat P., Claes L., Simon U. Trabecular bone fracture healing simulation with finite element analysis and fuzzy logic. J Biomech 2005, 38:2440-2450.
277. Lange J., Sapozhnikova A., Lu C., Hu D., Li X., Miclau T., et al. Action of IL-1β during fracture healing. J Orthop Res 2009, 28:778-784.
278. Kolar P., Gaber T., Perka C., Duda G.N., Buttgereit F. Human early fracture hematoma is characterized by inflammation and hypoxia. Clin Orthop Relat Res 2011, 469:3118-3126.
279. Chen Y., Whetstone H.C., Lin A.C., Nadesan P., Wei Q., Poon R., et al. β-Catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 2007, 4:e249.
280. Minear S., Leucht P., Miller S., Helms J.A. rBMP represses Wnt signaling and influences skeletal progenitor cell fate specification during bone repair. J Bone Miner Res 2010, 25:1196-1207.
281. Macsai C.E., Foster B.K., Xian C.J. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol 2008, 215:578-587.
282. Kolar P., Schmidt-Bleek K., Schell H., Gaber T., Toben D., Schmidmaier G., et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 2010, 16:427-434.
283. Grimsrud C.D., Romano P.R., D'Souza M., Puzas J.E., Schwarz E.M., Reynolds P.R., et al. BMP signaling stimulates chondrocyte maturation and the expression of Indian hedgehog. J Orthop Res 2001, 19:18-25.
284. Hiepen C., Benn A., Denkis A., Lukonin I., Weise C., Boergermann J.H., et al. BMP2-induced chemotaxis requires PI3K p55γ/p110α-dependent phosphatidylinositol (3,4,5)-triphosphate production and LL5β recruitment at the cytocortex. BMC Biol 2014, 12:43.
285. Spicer P.P., Kretlow J.D., Young S., Jansen J.A., Kasper F.K., Mikos A.G. Evaluation of bone regeneration using the rat critical size calvarial defect. Nat Protoc 2012, 7:1918-1929.
286. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007, 77:626-631.
287. Kloen P., Lauzier D., Hamdy R.C. Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions. Bone 2012, 51:59-68.
288. Mi M., Jin H., Wang B., Yukata K., Sheu T.-J., Ke Q.H., et al. Chondrocyte BMP2 signaling plays an essential role in bone fracture healing. Gene 2013, 512:211-218.
289. Kaplan F.S., Tabas J.A., Zasloff M.A. Fibrodysplasia ossificans progressiva: a clue from the fly?. Calcif Tissue Int 1990, 47:117-125.
290. Kaplan F.S., Pignolo R.J., Shore E.M. From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva. Expert Opin Orphan Drugs 2013, 1:637-649.
291. Kaplan F.S., Chakkalakal S.A., Shore E.M. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech 2012, 5:756-762.
292. Kaplan F.S., Groppe J., Pignolo R.J., Shore E.M. Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis. Ann N Y Acad Sci 2007, 1116:113-133.
293. Morales-Piga A., Bachiller-Corral F.J., Sanchez-Duffhues G. Is "fibrodysplasia ossificans progressiva" a vascular disease? A groundbreaking pathogenic model. Reumatol Clin 2014, 10:389-395.
294. la Peña de L.S., Billings P.C., Fiori J.L., Ahn J., Kaplan F.S., Shore E.M. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res 2005, 20:1168-1176.
295. Fiori J.L., Billings P.C., la Peña de L.S., Kaplan F.S., Shore E.M. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2006, 21:909.
296. Fukuda T., Kohda M., Kanomata K., Nojima J., Nakamura A., Kamizono J., et al. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 2009, 284:7149-7156.
297. de Gorter D.J.J., van Dinther M., ten Dijke P. Measurement of constitutive activity of BMP type I receptors. Constitutive activity in receptors and other proteins, part A 2010, vol. 484:281-293. Elsevier.
298. Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Cho T.-J., Choi I.H., et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006, 38:525-527.
299. van Dinther M., Visser N., de Gorter D.J.J., Doorn J., Goumans M.-J., de Boer J., et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 2010, 25:1208-1215.
300. Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L., et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009, 30:379-390.
301. Fukuda T., Kanomata K., Nojima J., Kokabu S., Akita M., Ikebuchi K., et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun 2008, 377:909.
302. Ohte S., Shin M., Sasanuma H., Yoneyama K., Akita M., Ikebuchi K., et al. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem Biophys Res Commun 2011, 407:213-218.
303. Groppe J.C., Wu J., Shore E.M., Kaplan F.S. In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 2011, 194:291-295.
304. Chaikuad A., Alfano I., Kerr G., Sanvitale C.E., Boergermann J.H., Triffitt J.T., et al. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 2012, 287:36990-36998.
305. Ramirez D.M., Ramirez M.R., Reginato A.M., Medici D. Molecular and cellular mechanisms of heterotopic ossification. Histol Histopathol 2014, 29:1281-1285.
306. Medici D., Olsen B.R. The role of endothelial-mesenchymal transition in heterotopic ossification. J Bone Miner Res 2012, 27:1619-1622.
307. Medici D., Olsen B.R. Transforming blood vessels into bone. Cell Cycle 2011, 10:362-363.
308. Forsberg J.A., Potter B.K. Heterotopic ossification in wartime wounds. J Surg Orthop Adv 2010, 19(1):54-61.
309. Liu X., Kang H., Shahnazari M., Kim H., Wang L., Larm O., et al. A novel mouse model of trauma induced heterotopic ossification. J Orthop Res 2013, 32:183-188.
310. Gannon F.H., Kaplan F.S., Olmsted E., Finkel G.C., Zasloff M.A., Shore E. Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum Pathol 1997, 28:339-343.
311. Yu P.B., Deng D.Y., Lai C.S., Hong C.C., Cuny G.D., Bouxsein M.L., et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med 2008, 14:1363-1369.
312. Sanvitale C.E., Kerr G., Chaikuad A., Ramel M.-C., Mohedas A.H., Reichert S., et al. A new class of small molecule inhibitor of BMP signaling. PLoS One 2013, 8:e62721.
313. Kugimiya F., Yano F., Ohba S., Igawa K., Nakamura K., Kawaguchi H., et al. Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem Biophys Res Commun 2005, 338:872-879.
314. Spiekerkoetter E., Tian X., Cai J., Hopper R.K., Sudheendra D., Li C.G., et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013, 123:3600-3613.
315. Tateishi K., Higuchi C., Ando W., Nakata K., Hashimoto J., Hart D.A., et al. The immunosuppressant FK506 promotes development of the chondrogenic phenotype in human synovial stromal cells via modulation of the Smad signaling pathway. Osteoarthritis Cartilage 2007, 15:709-718.
316. Darcy A., Meltzer M., Miller J., Lee S., Chappell S., Ver Donck K., et al. A novel library screen identifies immunosuppressors that promote osteoblast differentiation. Bone 2012, 50:1294-1303.
317. Grover V., Kapoor A., Malhotra R., Sachdeva S. Bone allografts: a review of safety and efficacy. Indian J Dent Res 2011, 22:496.
318. Lohmann C.H., Andreacchio D., Köster G., Carnes D.L., Cochran D.L., Dean D.D., et al. Tissue response and osteoinduction of human bone grafts in vivo. Arch Orthop Trauma Surg 2001, 121:583-590.
319. Ali I.H.A., Brazil D.P. Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br J Pharmacol 2014, 171:3620-3632.
320. Khan S.N., Lane J.M. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin Biol Ther 2004, 4:741-748.
321. Friedlaender G.E., Perry C.R., Cole J.D., Cook S.D., Cierny G., Muschler G.F., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg 2001, 83-A(Suppl. 1):S151-S158.
322. Schliephake H. Clinical efficacy of growth factors to enhance tissue repair in oral and maxillofacial reconstruction: a systematic review. Clin Implant Dent Relat Res 2015, 17:247-273.
323. Walker B., Koerner J., Sankarayanaryanan S., Radcliff K. A consensus statement regarding the utilization of BMP in spine surgery. Curr Rev Musculoskelet Med 2014, 7:208-219.
324. Tannoury C.A., An H.S. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J 2014, 14:552-559.
325. Woo E.J. Adverse events after recombinant human BMP2 in non-spinal orthopaedic procedures. Clin Orthop Relat Res 2013, 471:1707-1711.
326. Garrison K.R., Donell S., Ryder J., Shemitt I., Mugford M., Harvey I., et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review 2007, 11:1-150.
327. Nakamura Y., Wakitani S., Nakayama J., Wakabayashi S., Horiuchi H., Takaoka K. Temporal and spatial expression profiles of BMP receptors and noggin during BMP-2-induced ectopic bone formation. J Bone Miner Res 2003, 18:1854-1862.
328. Yang T., Chen S.L., Lu X.J., Shen C.Y., Liu Y., Chen Y.P. Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of Gremlin and transforming growth factor-β1. Mol Med Rep 2012, 6:246-252.
329. Hall D.E., Udvarhelyi G.B., Altman J. Lumbosacral skin lesions as markers of occult spinal dysraphism. JAMA 1981, 246:2606-2608.
330. Seemann P., Brehm A., König J., Reissner C., Stricker S., Kuss P., et al. Mutations in GDF5 reveal a key residue mediating BMP inhibition by NOGGIN. PLoS Genet 2009, 5:e1000747.
331. Schwaerzer G.K., Hiepen C., Schrewe H., Nickel J., Ploeger F., Sebald W., et al. New insights into the molecular mechanism of multiple synostoses syndrome (SYNS): mutation within the GDF5 knuckle epitope causes noggin-resistance. J Bone Miner Res 2012, 27:429-442.
332. Kim S., Kang Y., Krueger C.A., Sen M., Holcomb J.B., Chen D., et al. Sequential delivery of BMP-2 and IGF-1 using a chitosan gel with gelatin microspheres enhances early osteoblastic differentiation. Acta Biomater 2012, 8:1768-1777.
333. Hernández A., Reyes R., Sánchez E., Rodríguez-Évora M., Delgado A., Evora C. In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system. J Biomed Mater Res A 2012, 100:2382-2391.
334. Zheng Y., Wu G., Liu T., Liu Y., Wismeijer D., Liu Y. A novel BMP2-coprecipitated, layer-by-layer assembled biomimetic calcium phosphate particle: a biodegradable and highly efficient osteoinducer. Clin Implant Dent Relat Res 2013, 16:643-654.
335. Bae I.-H., Jeong B.-C., Kook M.-S., Kim S.-H., Koh J.-T. Evaluation of a thiolated chitosan scaffold for local delivery of BMP-2 for osteogenic differentiation and ectopic bone formation. BioMed Res Int 2013, 2013. 10 pp. 10.1155/2013/878930 (Article ID 878930).
336. Park S.-Y., Kim K.-H., Shin S.-Y., Koo K.-T., Lee Y.-M., Seol Y.-J. Dual delivery of rhPDGF-BB and bone marrow mesenchymal stromal cells expressing the BMP2 gene enhance bone formation in a critical-sized defect model. Tissue Eng Part A 2013, 19:2495-2505.
337. Lee J.-T., Jung J.-W., Choi J.-Y., Kwon T.-G. Enhanced bone morphogenic protein adenoviral gene delivery to bone marrow stromal cells using magnetic nanoparticle. J Korean Assoc Oral Maxillofac Surg 2013, 39:112-119.
338. Schwabe P., Greiner S., Ganzert R., Eberhart J., Dähn K., Stemberger A., et al. Effect of a novel nonviral gene delivery of BMP-2 on bone healing. Scientific World Journal 2012, 2012:560142-560149.
339. Beazley K.E., Nurminskaya M. The optimal carrier for BMP-2: a comparison of collagen versus fibrin matrix. Biotechnol Lett 2012, 132:1363-1370.